Abstract:
The present disclosure provides methods for sequencing nucleic acid targets (e.g., both DNA and RNA co-amplified in a sample mixture, for example by using a surrogate for the RNA). Such methods can be used to determine if one or more nucleic acid targets are present in a sample.
Abstract:
The present disclosure provides methods and kits for direct sequencing of nucleic acid targets. Such methods can be used to determine if one or more nucleic acid targets are present in a sample.
Abstract:
This disclosure concerns the identification of biomarkers that are characteristic of squamous or non squamous (e.g., adenocarcinoma, large cell carcinoma, carcinoid tumor, sarcomatoid carcinoma) subtypes of non small cell lung cancer (NSCLC), clinically useful NSCLC classifiers, kits and arrays for distinguishing squamous and nonsquamous NSCLC subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing.
Abstract:
The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5′-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
Abstract:
The present disclosure provides methods of using quantitative nuclease protection sequencing (qNPS) methods to evaluate epitranscriptomes. The disclosed methods capture nucleic acid molecules that are modified as a result of exposure to an agent, such as stress, a mutagen, a microbe (such as a pathogen), or therapeutic agent. The resulting modified nucleic acid molecules are then directly or indirectly sequenced using nuclease protection probes (NPPs) and qNPS, allowing for the detection of target and off-target modifications of an epitranscriptome.
Abstract:
The present disclosure provides methods and kits for direct sequencing of nucleic acid targets. Such methods can be used to determine if one or more nucleic acid targets are present in a sample.